Advertisement

Keywords

Renal Insufficiency Dialysis Patient Chemical Formula Plasma Protein Binding Common Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

Main reference

  1. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1247, chapter 55, Antiproliferative agents and drugs used for immunosuppression by P Calabresi and RE ParksGoogle Scholar

Main reference

  1. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1247, chapter 55, Antiproliferative agents and drugs used for immunosuppression by P Calabresi and RE ParksGoogle Scholar
  2. Tattersall MHN, Sodergren JE, Sengupta SK, Trites DH, Modest EJ, Frei E: Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 17:701, 1975PubMedGoogle Scholar

Main reference

  1. Braun P, Leyendecker G, Nocke W: Danazol. Pharmakologische Grundlagen und klinische Anwendung. Gynäkologe 12:219, 1979Google Scholar
  2. Davison C, Banks W, Fritz A: The absorption, distribution and metabolic fate of danazol in rats, monkeys and human volunteers. Arch Int Pharmacodyn Ther 221:294, 1976PubMedGoogle Scholar
  3. Dmowski WP: Endocrine properties and clinical application of danazol. Fertil Steril 31:237, 1979PubMedGoogle Scholar
  4. Geirregat R: Pharmacology and pharmacodynamics of danazol, a condensed survey of current knowledge. Benelux Symp Danatrol 1978 p 13Google Scholar
  5. Lloyd-Jones JG, Labross A, Wiliiams-Ross T, Ross RW, Edelson J, Davison C: Danazol plasma concentration in man. J Int Med Res 5 (Suppl 3): 18, 1977PubMedGoogle Scholar
  6. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1395, danazolGoogle Scholar
  7. Potts GO: Pharmacology of Danazol. J Int Med Res 5 (Suppl 3):1, 1977PubMedGoogle Scholar
  8. Potts GO, Schane HP, Edelson J: Pharmacology and pharmacokinetics of danazol. Drugs 19:321, 1980PubMedCrossRefGoogle Scholar

Main reference

  1. Dykes MHM: Evaluation of a muscle relaxant: Dantrolene sodium (Dantrium). JAMA 231:862, 1975PubMedCrossRefGoogle Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1232, dantrolene sodiumGoogle Scholar
  3. Schneider R, Mitchell D: Dantrolene hepatitis. JAMA 235:1590, 1976PubMedCrossRefGoogle Scholar
  4. Vallner JJ, Honigberg LL, Stewart JT, Peyton AB: Dantrolene and metabolite levels in six patients on chronic therapy. Curr Ther Res 25:79, 1979Google Scholar

Main reference

  1. Anderson RJ, Bennett WM, Gambertoglio JG, et al.: Fate of drugs in renal failure; In: Brenner B, Rèctor F (eds): The kidney. Philadelphia: WB Saunders, 1981 p 2659Google Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:558, dapsoneGoogle Scholar
  3. Reidenberg MM, Drayer DE: Effects of renal disease upon drug disposition. Drug Metab Rev 8:293, 1978PubMedCrossRefGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:622, daunorubicin hydrochlorideGoogle Scholar

Main reference

  1. Bar-Meir S, Levy R, Halperin Z, Levy-Gigi C, Gilat T: Impairment of bromosulfophthalein clearance by bile salt administration in normal volunteers and patients with Dubin-Johnson syndrome. Isr J Med Sci 18:211, 1982PubMedGoogle Scholar
  2. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:994, chapter 43, Laxatives by LL BruntonGoogle Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1563, dehydrocholic acidGoogle Scholar
  4. Ogura M, Yamasaki K: The fate of C14-labeled dehydrocholic acid in guinea pig. J Biochem (Tokyo) 49:649, 1961Google Scholar
  5. Schulze PJ, Czok G, Meyer H: The influence of cholic acid and dehydrocholic acid on the biliary excretion of unconjugated and conjugated sulfobromophthalein in rats. Arzneimittelforschung (Drug Res) 26:1894, 1976Google Scholar

Main reference

  1. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1170, chapter 52, Antimicrobial agents by MA Sande and GL MandellGoogle Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:215, demeclocyclineGoogle Scholar

Main reference

  1. Ackrill P, Day JP: Desferrioxamine in the treatment of aluminium overload. Clin Nephrol 24 (Suppl 1):S94, 1985PubMedGoogle Scholar
  2. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R: Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet I:652, 1982CrossRefGoogle Scholar
  3. Chang TMS, Barre P: Effect of desferrioxamine on removal of aluminium and iron by coated charcoal haemoperfusion and haemodialysis. Lancet II:1051, 1983CrossRefGoogle Scholar
  4. Hercz G, Salusky IB, Norris KC, Fine RN, Coburn JW: Aluminium removal by peritoneal dialysis: Intravenous vs. intraperitoneal deferoxamine. Kidney Int 30:944, 1986PubMedCrossRefGoogle Scholar
  5. Milliner DS, Hercz G, Miller JH, Shinaberger JH, Nissenson AR, Coburn JW: Clearance of aluminium by hemodialysis: Effect of desferrioxamine. Kidney Int 29 (Suppl 18):S100, 1986Google Scholar
  6. Rembold CM, Krumlovsky FA, Röxe DM, Fitzsimmons E, del Greco F: Treatment of hemodialysis with desferrioxamine. Trans Am Soc Artif Intern Organs 28:621, 1982PubMedGoogle Scholar
  7. Schmidt H, Scheuermann EH, Werner E, Kaltwasser JP, Schoeppe W, Baldamus CA: Iron (Fe) and aluminium (AI) removal in ESRD patients treated with desferrioxamine (DFO). Blood Purif 1:56, 1983Google Scholar
  8. Simon P, Allain P, Ang KS, Cam G, Mauras Y: Prevention and treatment of aluminium intoxication in chronic renal failure. Adv Nephrol 14:439, 1985Google Scholar

Main reference

  1. Achong MR, Keane PM: Pheochromocytoma unmasked by desipramine therapy. Ann Intern Med 94:358, 1981PubMedGoogle Scholar
  2. Farman JV: Desipramine and hypertensive episodes. Lancet II:436, 1966CrossRefGoogle Scholar
  3. Lieberman JA, Cooper TB, Suckow RF, Steinberg H, Borenstein M, Brenner R, Kane JM: Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 37:301, 1985PubMedCrossRefGoogle Scholar
  4. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:363, desipramineGoogle Scholar
  5. Nagy A, Johansson R: Plasma levels of imipramine and desipramine in man after different routes of administration. Naunyn Schmiedebergs Arch Pharmacol 290:145, 1975PubMedCrossRefGoogle Scholar
  6. Robinson DS, Nies A: Increased steady-state plasma levels and prolonged half-lives of tricyclic antidepressants in the elderly. Clin Pharmacol Ther 21:116, 1977Google Scholar
  7. Veith RC, Friedel RO, Bloom V, Bielski R: Electrocardiogram changes and plasma desipramine levels during treatment of depression. Clin Pharmacol Ther 27:796, 1980PubMedCrossRefGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1135, desmopressinGoogle Scholar

Main reference

  1. Kawai S, Ichikawa Y, Homma M: Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal disease: accelerated metabolism of dexamethasone in renal failure. J Clin Endocrinol Metab 60:848, 1985PubMedCrossRefGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1440, dexamphetamine sulphate.Google Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1441, dexamphetamine phosphate.Google Scholar

Main reference

  1. Chiou WL, Athanikar NA, Huang SM: Long half-life of chlorpheniramine. N Engl J Med 300:501, 1979PubMedGoogle Scholar
  2. Lai CM, Stoll RG, Look ZM, Yacobi A: Urinary excretion of chlorpheniramine and pseudoephedrine in humans. J Pharm Sci 68:1243, 1979PubMedCrossRefGoogle Scholar
  3. Miyazaki H, Abuki H: Mass fragmentographic determination of d-and l-chlorpheniramine with aid of the stable isotope technique. Chem Pharm Bull (Tokyo) 24:2572, 1976CrossRefGoogle Scholar
  4. Peets EA, Jackson M, Symchowicz S: Metabolism of chlorpheniramine maleate in man. J Pharmacol Exp Ther 180:464, 1972Google Scholar

Main reference

  1. Arturson G, Wallenius G: The renal clearance of dextran of different molecular sizes in normal humans. Scand J Clin Lab Invest 16:81, 1964PubMedCrossRefGoogle Scholar
  2. Köhler H, Kirch W, Höffler D, Koeppe P: Pharmakokinetik und Dosierung von Dextran 40 in Abhängigkeit von der Nierenfunktion. Klin Wochenschr 52:1111, 1974PubMedCrossRefGoogle Scholar
  3. Köhler H, Weihrauch TR, Hegel P, Kirch W, Höffler D: Dosierung und Elimination von Dextran 40 bei Hämodialysepatienten. Klin Wochenschr 53:523, 1975PubMedCrossRefGoogle Scholar
  4. Köhler H, Kirch W, Klein H, Distler A: Die Volumenwirkung von 6% Hydroxyäthylstärke 450/0,7, 10% Dextran und 3,5% isozyanatvernetzter Gelatine bei Patienten mit terminaler Niereninsuffizienz. Anaesthesist 27:421, 1978PubMedGoogle Scholar
  5. Köhler H, Zschiedrich H, Clasen R, Linfante A, Gamm H: Blutvolumen, kolloidosmotischer Druck und Nierenfunktion von Probanden nach Infusion mittelmolekularer 10% Hydroxyäthylstärke 200/0,5 und Dextran 40. Anaesthesist 31:61, 1982PubMedGoogle Scholar
  6. Mailloux LU, Swartz CD, Capizzi R, Kim KE, Onesti G, Ramirez O, Brest AN: Acute renal failure after administration of low-molecular weight dextran infusion. N Engl J Med 277:1113, 1967PubMedCrossRefGoogle Scholar
  7. Morgan TO, Little JM, Evans WA: Renal failure associated with low-molecular-weight dextran infusion. Br Med J 2:737, 1966PubMedCrossRefGoogle Scholar
  8. Ring J, Meßmer K: Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1:466, 1971Google Scholar
  9. Schmitt M, Cremer W: Dextran 40-induziertes Akutes Nierenversagen. Nieren- und Hochdruckkrankh 12:301, 1983Google Scholar

Main reference

  1. Arturson G, Wallenius G: The renal clearance of dextran of different molecular sizes in normal humans. Scand J Clin Lab Invest 16:81, 1964PubMedCrossRefGoogle Scholar
  2. Köhler H, Kirch W, Höffler D, Koeppe P: Pharmakokinetik und Dosierung von Dextran 40 in Abhängigkeit von der Nierenfunktion. Klin Wochenschr 52:1111, 1974PubMedCrossRefGoogle Scholar
  3. Köhler H, Weihrauch TR, Fiegel P, Kirch W, Höffler D: Dosierung und Elimination von Dextran 40 bei Hämodialysepatienten. Klin Wochenschr 53:523, 1975PubMedCrossRefGoogle Scholar
  4. Mailloux LU, Swartz CD, Capizzi R, Kim KE, Onesti G, Ramirez O, Brest AN: Acute renal failure after administration of low-molecular weight dextran infusion. N Engl J Med 277:1113, 1967PubMedCrossRefGoogle Scholar
  5. Morgan TO, Little JM, Evans WA: Renal failure associated with low-molecular-weight dextran infusion. Br Med J 2:737, 1966PubMedCrossRefGoogle Scholar
  6. Ring J, Meßmer K: Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1:466, 1971Google Scholar

Main reference

  1. Aylward M, Maddock J, Davies DE, Protheroe DA, Leideman T: Dextromethorphan and codeine: Comparison of plasma kinetics and antitussive effects. Eur J Respir Dis 65:283, 1984PubMedGoogle Scholar
  2. Calesnick B, Christensen JA: Latency of cough response as a measure of antitussive agents. Clin Pharmacol Ther 8:374, 1967PubMedGoogle Scholar
  3. Versie R, Noirfalise A, Neven M, Malchair R: The toxicity and metabolism of 3-methoxy-N-methyl morphinane (Romilar) in the child. Ann Med Leg (Paris) 42:561, 1962Google Scholar
  4. Willner K: Ausscheidung und Abbau von (+)-3-Methoxy-N-methylmorphinan und seinen entmethylierten Derivaten beim Menschen. Arzneimittelforschung (Drug Res) 13:26, 1963Google Scholar

Main reference

  1. Bantle JP, Oppenheimer JH, Schwartz HL, Hunninghake DB, Probstfield JL, Hanson RF: TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine. Metabolism 30:63, 1981PubMedCrossRefGoogle Scholar
  2. Boyd GS, Oliver MF: Thyroid hormones and plasma lipids. B Med Bull 16:138, 1960Google Scholar
  3. Gorman CA, Jiang NS, Ellefson RD, Elveback LR: Comparative effectiveness of dextrothyroxine and levothyroxine in correcting hypothyroidism and lowering blood lipid levels in hypothyroid patients. J Clin Endocrinol Metab 49:1, 1979PubMedCrossRefGoogle Scholar
  4. Hüfner M, Grußendorf M: D-Thyroxin: Wirkungen, Metabolismus und Nebenwirkungen. Aktuel Endokrinol Stoffw 3:108, 1982Google Scholar
  5. Margolis S: Treatment of hyperlipemia. JAMA 239:2696, 1978PubMedCrossRefGoogle Scholar
  6. The Coronary Drug Project Research Group: The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 220:996, 1972CrossRefGoogle Scholar
  7. Strisower EH, Adamson G, Strisower B: Treatment of hyperlipidemias. Am J Med 45:488, 1968PubMedCrossRefGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:863, diatrizoic acidGoogle Scholar

Main reference

  1. Balogh A, Fünfstück R, Demme U, Kangas L, Sperschneider H, Traeger A, Stein G, Pekkarinen A: Dialysability of benzodiazepines by haemodialysis and controlled sequential ultrafiltration (CSU) in vitro. Acta Pharmacol Toxicol (Copenh) 49:174, 1981CrossRefGoogle Scholar
  2. Klotz U, Kangas L, Kants J: Clinical pharmacokinetics of benzodiazepines. Prog in Pharmacol vol. 3, Stuttgart: G. Fischer Verlag, 1980Google Scholar
  3. Mandelli M, Tognoni G, Garattini S: Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 3:72, 1978PubMedCrossRefGoogle Scholar
  4. Ochs HR, Greenblatt DJ, Kaschell HJ, Klehr U, Divoll M, Abernethy DR: Diazepam kinetics in patients with renal insufficiency or hyperthyroidism Br J Clin Pharmacol 12:828, 1981CrossRefGoogle Scholar

Main reference

  1. Koch-Weser J: Vasodilator drugs in the treatment of hypertension. Arch Intern Med 133:1017, 1974PubMedCrossRefGoogle Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:476, diazoxideGoogle Scholar
  3. Ogilvie RI, Nadeau JH, Sitar DS: Diazoxide concentration-response relation in hypertension. Hypertension 4:167, 1982PubMedCrossRefGoogle Scholar
  4. O’Malley K, Velasco M, Pruitt A, McNay JL: Decreased plasma protein binding of diazoxide in uremia. Clin Pharmacol Ther 18:53, 1975PubMedGoogle Scholar
  5. Pearson RM: Pharmacokinetics and response to diazoxide in renal failure. Clin Pharmacokiet 2:198, 1977CrossRefGoogle Scholar
  6. Pohl JEF, Thurston H: Use of diazoxide in hypertension with renal failure. Br Med J 4:142, 1971PubMedCrossRefGoogle Scholar
  7. Pruitt AW, Faraj BA, Dayton PG: Metabolism of diazoxide in man and experimental animals. J Pharmacol Exp Ther 188:248, 1974PubMedGoogle Scholar
  8. Sellers EM, Koch-Weser J: Protein binding and vascular activity of diazoxide. N Engl J Med 281:1141, 1969PubMedCrossRefGoogle Scholar

Main reference

  1. Campillo JA, Lanao JM, Dominguez-Gil A, Rubio F, Martin A: Disposition of dibekacin in patients undergoing haemodialysis. Eur J Clin Pharmacol 18:347, 1980PubMedCrossRefGoogle Scholar
  2. Leroy A, Humbert G, Fillastre JP: Pharmacokinetics of dibekacin in normal subjects and in patients with renal failure. J Antimicrob Chemother 6:113, 1980PubMedCrossRefGoogle Scholar
  3. Viotte G, Leroy A, Godin M, Fillastre JP: Pharmacocinetique de la dibekacine chez le malade ayant une insuffisance renale chronique. Nouv Presse Med 11:3414, 1982PubMedGoogle Scholar

Main reference

  1. Gauch R, Modestin J: Zur Pharmakokinetik von Dibenzepin. Arzneimittelforschung (Drug Res) 23:687, 1973Google Scholar
  2. Lehner H, Gauch R, Michaelis W: Zum Stoffwechsel von 5-Methyl-10-β-dimethylaminoäthyl-10, 11-dihydro-11-oxo-5H-di-benzo-(b,e)(1,4)-diazepin-HCl. Arzneimittelforschung (Drug Res) 17:185, 1967Google Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:360, dibenzepin hydrochlorideGoogle Scholar
  4. Modestin J: Über die Abhängigkeit der klinischen Wirksamkeit des Dibenzepins (Noveril) von seiner Plasma-Konzentration. Pharmakopsychiatrie 6:29, 1973CrossRefGoogle Scholar
  5. O’Malley K, Crooks J, Duke E, Stevenson TH: Effect of age and sex on human drug metabolism. Br Med J 3:607, 1971PubMedCrossRefGoogle Scholar

Main references

  1. Igarishi K, Kasuya F, Fukui M: Metabolism of dibucaine: Isolation and identification of urinary basic metabolites in the rat, rabbit and man. J Pharmacobiodyn 6:538, 1983CrossRefGoogle Scholar
  2. Tucker GT, Boyes RN, Bridenbaugh PO, Moore DC: Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physiochemical properties, and anesthetic activity. Anesthesiology 33:287, 1970PubMedCrossRefGoogle Scholar
  3. Tucker GT, Mather LE: Clinical pharmacokinetics of local anaesthetic agents. Clin Pharmacokinet 4:241, 1979PubMedCrossRefGoogle Scholar

Main references (General)

  1. Brombacher PJ, Cremers HMHG, Verheesen PE, Quanjel-Schreurs RAM: Quantitative determination of sodium-o-((2,6-dichlorophenyl)-amino)phenyl-acetate (Diclofenac) in human blood plasma or serum. Arzneimittelforschung (Drug Res) 27(II): 1597, 1977Google Scholar
  2. Godbillon J, Gauron S, Metayer JP: High-performance liquid chromatographic determination of diclofenac and its monohydroxylated metabolites in biological fluids. J Chromatogr 338:151, 1985PubMedCrossRefGoogle Scholar
  3. John VA: The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man. Rheumatol Rehabil Suppl 2:22, 1979Google Scholar
  4. Riess W, Stierlin H, Faigle JW, Geiger UP, Gerardin A, Schmid K, Sulc M, Wagner J, Theobald W: Kinetik und Biotrans-formation von Diclofenac in Tier und Mensch. Therapiewoche 26:2891, 1976Google Scholar
  5. Stierlin H, Faigle JW, Colombi A: Pharmacokinetics of diclofenac sodium (Voltaren) and metabolites in patients with impaired renal function. Scand J Rheumatol (Supl 22):30, 1978Google Scholar
  6. Wagner J, Sulc M: Bindung von Diclofenac-Na (Voltaren) an Serumproteine verschiedener Spezies und Interaktionen mit anderen Pharmaka. Akt Rheumatol 4:153, 1979Google Scholar
  7. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG: The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 16:405, 1979 (Renal damage:)PubMedCrossRefGoogle Scholar
  8. Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 4:1, 1984PubMedCrossRefGoogle Scholar
  9. Carmichael J, Shankel SW: Effects of non-steroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992, 1985PubMedCrossRefGoogle Scholar
  10. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563, 1984PubMedCrossRefGoogle Scholar
  11. Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 18:553, 1980PubMedCrossRefGoogle Scholar
  12. Dunn MJ: Non-steroidal anti-inflammatory drugs and renal function. Annu Rev Med 35:411, 1984PubMedCrossRefGoogle Scholar
  13. Hart D, Lifschitz MD: Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am J Nephrol 7:408, 1987PubMedCrossRefGoogle Scholar
  14. Henrich WL: Nephrotoxicity of nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2:478, 1982Google Scholar
  15. Orme ML’E: Non-steroidal anti-inflammatory drugs and the kidney. Br Med J 292:1521, 1986CrossRefGoogle Scholar
  16. Reeves WB, Foley RJ, Weinman EJ: Renal dysfunction from nonsteroidal anti-inflammatory drugs. Arch Intern Med 144:1943, 1984PubMedCrossRefGoogle Scholar
  17. Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (First of two parts). N Engl J Med 302:1179, 1980PubMedCrossRefGoogle Scholar
  18. Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (Second of two parts). N Engl J Med 302:1237, 1980PubMedCrossRefGoogle Scholar
  19. Torres VE: Present and future of non-steroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc 57:389, 1982PubMedGoogle Scholar
  20. Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DG: Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int 30:760, 1986PubMedCrossRefGoogle Scholar
  21. Wegmüller E: Nicht-steroidale Antirheumatika und Nephrotoxizität. Dtsch Med Wochenschr 110:469, 1985PubMedCrossRefGoogle Scholar

Main references

  1. Bulger RJ, Lindholm DD, Murray JS, Kirby WMM: Effect of uremia on methicillin and oxacillin blood levels. Excretion and inactivation in renal failure and hemodialysis. JAMA 187:319, 1964PubMedCrossRefGoogle Scholar
  2. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50, Antimicrobial agents by GL Mandell and MA SandeGoogle Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:215, dicloxacillin sodiumGoogle Scholar

Main references

  1. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1338, chapter 58, Anticoagulant, antithrombotic, and thrombolytic drugs by RA O’ReillyGoogle Scholar
  2. Jaenecke JP: In: Antikoagulantien- und Fibrinolysetherapie. 3. Auflage, Stuttgart, New York: Georg Thieme, 1982 p 19Google Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:339, dicoumarol.Google Scholar

Main references

  1. Bangham DR: Metabolism and excretion of 14C labelled diethyl-carbamazine. Br J Pharmacol 10:397, 1955Google Scholar
  2. Edwards G, Awadzi K, Breckenridge AM, Gilles HM, Orme ML’E, Ward SA: Diethylcarbamazine disposition in patients with onchocerciasis. Clin Pharmacol Ther 30:551, 1981PubMedCrossRefGoogle Scholar
  3. Harned BK, Cunningham RW, Halliday S, Vessery RE, Yuda NN, Clark MC, Hine CH, Cosgrove R, Subbarow Y: Studies on the chemotherapy of filariasis VI. Some pharmacodynamic properties of 1-diethylcarbamyl-4-methylpiperazine hydrochloride hetrazan. J Lab Clin Med 33:216, 1948PubMedGoogle Scholar
  4. Harned BK, Cunningham RW, Halliday S, Vessey RE, Yuda NN, Clark MC, Hine CH, Cosgrove R., Subbarow Y: Studies on the chemotherapy of filariasis VI. Some pharmacodynamic properties of 1-diethylcarbamyl-4-methylpiperazine hydrochloride, hetrazam. J Lab Clin Med 33:216, 1948PubMedGoogle Scholar
  5. Hawking F: Diethylcarbamazine and new compounds for the treatment of filariasis. Adv Pharmacol Chemother 16:129, 1979PubMedCrossRefGoogle Scholar
  6. Katner H, Beyt BE jr, Krotoski WA: Loiasis and renal failure. South Med J 77:907, 1984PubMedCrossRefGoogle Scholar
  7. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:51, diethylcarbamazine acid citrate. (Main reference)Google Scholar
  8. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1413, diethylstilbestrolGoogle Scholar

Main references General

  1. Chan LK, Winearls CG, Oliver DO, Dunnill MS: Acute interstitial nephritis and erythroderma associated with diflunisal, Br Med J 1:84, 1980CrossRefGoogle Scholar
  2. Levy G: Decreased body clearance of diflunisal in renal insufficiency — An alternative explanation. Br J Clin Pharmacol 8:601. 1979PubMedCrossRefGoogle Scholar
  3. Tempero KF, Cirillo VJ, Steelman SL: Diflunisal: A review of pharmacokinetic and pharmacodynamic properties, drug interactions, and special tolerability studies in humans. Br J Clin Pharmacol 4 (Suppl. 1):31S, 1977PubMedCrossRefGoogle Scholar
  4. Tocco DJ, Breault GO, Zacchei AG, Steelman SL, Perrier CV: Physiological disposition and metabolism of 5-(2′,4′-difluoro-phenyDsalicyclic acid, a new salicylate. Drug Metab Dispos 3:453, 1975PubMedGoogle Scholar
  5. Verbeeck RK, Tjandramaga TB, Mullie A, Verbesselt R, Verberckmoes R, De Schepper PJ: Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency. Br J Clin Pharmacol 7:273, 1979PubMedCrossRefGoogle Scholar
  6. Verbeeck RK, Boel A, Buntinx A, De Schepper PJ: Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic. Biochem Pharmacol 29:571, 1980PubMedCrossRefGoogle Scholar
  7. Verbeeck RK, De Schepper PJ: Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding. Clin Pharmacol Ther 27:628, 1980PubMedCrossRefGoogle Scholar
  8. Wharton JG, Oliver DO, Dunnill MS: Acute renal failure associated with diflunisal. Postgrad Med J 58:104, 1982 (Renal damage):PubMedCrossRefGoogle Scholar
  9. Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 4:1, 1984PubMedCrossRefGoogle Scholar
  10. Carmichael J, Shankel SW: Effects of non-steroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992, 1985PubMedCrossRefGoogle Scholar
  11. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563, 1984PubMedCrossRefGoogle Scholar
  12. Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 18:553, 1980PubMedCrossRefGoogle Scholar
  13. Dunn MJ: Non-steroidal anti-inflammatory drugs and renal function. Annu Rev Med 35:411, 1984PubMedCrossRefGoogle Scholar
  14. Hart D, Lifschitz MD: Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am J Nephrol 7:408, 1987PubMedCrossRefGoogle Scholar
  15. Henrich WL: Nephrotoxicity of nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2:478, 1982Google Scholar
  16. Orme ML’E: Non-steroidal anti-inflammatory drugs and the kidney. Br Med J 292:1521, 1986CrossRefGoogle Scholar
  17. Reeves WB, Foley RJ. Weinman EJ: Renal dysfunction from nonsteroidal anti-inflammatory drugs. Arch Intern Med 144:1943, 1984CrossRefGoogle Scholar
  18. Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (First of two parts). N Engl J Med 302:1179, 1980PubMedCrossRefGoogle Scholar
  19. Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (Second of two parts). N Engl J Med 302:1237, 1980PubMedCrossRefGoogle Scholar
  20. Torres VE: Present and future of non-steroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc 57:389, 1982PubMedGoogle Scholar
  21. Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DG: Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int 30:760, 1986PubMedCrossRefGoogle Scholar
  22. Wegmüller E: Nicht-steroidale Antirheumatika und Nephrotoxizität. Dtsch Med Wochenschr 110:469, 1985PubMedCrossRefGoogle Scholar

Main references

  1. Anderson RJ, Melikian DM, Gambertoglio JG et al.: Prescribing medication in long-term dialysis units. Arch Intern Med 142:1305, 1982PubMedCrossRefGoogle Scholar
  2. Aronson JK: Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction. Clin Pharmacokinet. 8:155, 1983PubMedCrossRefGoogle Scholar
  3. Chazan JA, Pono LM: Sudden death in patients with chronic renal failure on hemodialysis. Dialysis Transplant 16:447, 1987Google Scholar
  4. Doherty JE: Digitalis glycosides. Ann Intern Med 79:229, 1973PubMedGoogle Scholar
  5. Erdmann E, Beukelmann D, Brown L: Digitalisrezeptoren bei Dialysepatienten. In: Schölmerich P, Kleinsorge H (eds): Apparative Technik und Pharmakotherapie. Stuttgart, New York: S. Fischer, 1986Google Scholar
  6. Finkelstein FO, Goffinet JA, Hendler ED, Lindenbaum J: Pharmacokinetics of digoxin and digitoxin in patients undergoing hemodialysis. Am J Med 58:525, 1975PubMedCrossRefGoogle Scholar
  7. Gault MH, Kalra J, Longerich L, Dawe M: Digoxigenin biotransformation. Clin Pharmacol Ther 31:695, 1982PubMedCrossRefGoogle Scholar
  8. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed, New York: Macmillan, 1985:716, chapter 30, Digitalis and allied cardie glycosides by BF Hoffman and T Bigger.Google Scholar
  9. Grabensee B, Peters U, Risler T: Digitalisglykoside und Niereninsuffizienz. Internist 22:622, 1981PubMedGoogle Scholar
  10. Graves PE, Fenster PE, MacFarland RT, Marcus FI, Perrier D: Kinetics of digitoxin and the bis- and monodigitoxosides of digitoxigenin in renal insufficiency. Clin Pharmacol Ther 36:607. 1984PubMedCrossRefGoogle Scholar
  11. Haustein KO: Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment. Eur J Clin Pharmacol 19:45, 1981PubMedCrossRefGoogle Scholar
  12. Jick H: Adverse drug effects in relation to renal function. Am J Med 62:514, 1977PubMedCrossRefGoogle Scholar
  13. Keller F, Schwarz A, Offermann G, Molzahn M, Distler A, Kreutz G, Weinmann J, von Leitner ER: Digitalisauslassversuch bei Hämodialysepatienten. Dtsch Med Wochenschr 109:290, 1984PubMedCrossRefGoogle Scholar
  14. Kramer P, Quellhorst E, Horenkamp J, Scheler F: Dialysance und prozentuale Elimination verschiedener Herzglykoside während Hämodialyse und Peritonealdialyse. Klin Wochenschr 50:609, 1972PubMedCrossRefGoogle Scholar
  15. Kramer P: Digitalis pharmacokinetics and therapy with respect to impaired renal function. Klin Wochenschr 55:1, 1977PubMedCrossRefGoogle Scholar
  16. Kramer W, Wizemann V, Thormann J, Bechtold A, Schütterle G, Lasch HG: Mechanism of altered myocardial contractility during hemodialysis: Importance of changes in the ionized calcium to plasma potassium ratio. Klin Wochenschr 63:272, 1985PubMedCrossRefGoogle Scholar
  17. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:824, digitoxinGoogle Scholar
  18. Peters U: Klinische und pharmakologische Grundlagen für eine kontrollierte Digitalistherapie. Z Kardiol 69:247, 1980PubMedGoogle Scholar
  19. Rambausek M, Ritz E: Digitalis in chronic renal insufficiency. Blood Purif 3:4, 1985PubMedCrossRefGoogle Scholar
  20. Smith TW, Haber E: Digitalis. N Engl J Med 289:1010, 1973PubMedCrossRefGoogle Scholar
  21. Storstein L: Studies on digitalis. II. The influence of impaired renal function on the renal excretion of digitoxin and its cardioactive metabolites. Clin Pharmacol Ther 16:25, 1974PubMedGoogle Scholar
  22. Storstein L: Studies on digitalis. V. The influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of digitoxin and digoxin. Clin Pharmacol Ther 20:6, 1976PubMedGoogle Scholar
  23. Storstein L, Janssen H: Studies on digitalis. VI. The effect of heparin on serum protein binding of digitoxin and digoxin. Clin Pharmacol Ther 20:15, 1976PubMedGoogle Scholar
  24. Voehringer HF, Rietbrock N: Digitalis therapy in renal failure with special regard to digitoxin. Int J Clin Pharmacol Ther Toxicol 19:175, 1981Google Scholar

Main references

  1. Anderson RJ, Melikian DM, Gambertoglio JG et al.: Prescribing medication in long-term dialysis units. Arch Intern Med 142:1305, 1982PubMedCrossRefGoogle Scholar
  2. Aronson JK: Clinical pharmacokinetics of digoxin 1980. Clin Pharmacokinet 5:137, 1980PubMedCrossRefGoogle Scholar
  3. Aronson JK: Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction. Clin Pharmacokinet 8:155, 1983PubMedCrossRefGoogle Scholar
  4. Brown D, Juhl R: Decreased bioavailability of digoxin due to antacids and kaolinpectin. N Engl J Med 295:1034, 1976PubMedCrossRefGoogle Scholar
  5. Caldwell JH, Cline CT: Biliary excretion of digoxin in man. Clin Pharmacol Ther 19:410, 1975Google Scholar
  6. Chazan JA, Pono LM: Sudden Death in patients with chronic renal failure on hemodialysis. Dialysis Transplant 16:447, 1987Google Scholar
  7. Christiansen HJB, Kolenforf K, Siersbaek-Nielsen K, Hansen JM: Serum digoxin values following a dosage regimen based on body weight, sex, age and renal function. Acta Med Scand 194:257, 1973PubMedCrossRefGoogle Scholar
  8. Doherty JE: Digitalis glycosides. Ann Intern Med 79:229, 1973PubMedGoogle Scholar
  9. Erdmann E, Beukelmann D, Brown L: Digitalisrezeptoren bei Dialysepatienten. In: Schölmerich P, Kleinsorge H (eds): Apparative Technik und Pharmakotherapie. Stuttgart, New York: S. Fischer, 1986Google Scholar
  10. Evered DC, Chapman C: Plasma digoxin concentrations and digoxin toxicity in hospital patients. Br Heart J 33:540, 1970CrossRefGoogle Scholar
  11. Ewy GA, Kapadia GG, Yao L, Lullin M, Marcus FI: Digoxin metabolism in the elderly. Circulation 39:449, 1969PubMedCrossRefGoogle Scholar
  12. Fenster PE, Hager WD, Perrier D et al.: Digoxin-quinidine interaction in patients with chronic renal failure. Circulation 66:1277, 1982PubMedCrossRefGoogle Scholar
  13. Finkelstein FO, Goffinet JA, Hendler ED, Lindenbaum J: Pharmacokinetics of digoxin and digitoxin in patients undergoing hemodialysis. Am J Med 58:525, 1975PubMedCrossRefGoogle Scholar
  14. Flasch H: Bioverfügbarkeit von Digoxin. Dtsch Med Wochenschr 104:1243, 1979PubMedGoogle Scholar
  15. Gault MH, Jeffrey JR, Chirito E, Ward LL: Studies of digoxin dosage, kinetics and serum concentration in renal failure and review of the literature. Nephron 17:161, 1976PubMedCrossRefGoogle Scholar
  16. Gault MH, Churchill DN, Kalra J: Loading dose of digoxin in renal failure. Br J Clin Pharmacol 9:593, 1980PubMedCrossRefGoogle Scholar
  17. Gault MH, Gallaway B, Fine A, Vasdev S: Rising serum digoxin without further dosage in acute renal failure. Nephron 37:190, 1984PubMedCrossRefGoogle Scholar
  18. Gault MH, Kalra J, Longerich L, Dawe M: Digoxigenin biotransformation. Clin Pharmacol Ther 31:695, 1982PubMedCrossRefGoogle Scholar
  19. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:716. chapter 30, Digitalis and allied cardiac glycosides by BF Hoffman and T Bigger.Google Scholar
  20. Grabensee B, Peters U, Risler T: Digitalisglykoside und Niereninsuffizienz. Internist 22:622, 1981PubMedGoogle Scholar
  21. Haustein KO: Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment. Eur J Clin Pharmacol 19:45, 1981PubMedCrossRefGoogle Scholar
  22. Hirschberg R, Schaefer K, von Herrath D, Kreutz G, Kewitz H: Digoxin-quinidine interaction in patients with renal failure. Klin Wochenschr. 59:521, 1981PubMedCrossRefGoogle Scholar
  23. lisolo E: Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 2:1, 1977CrossRefGoogle Scholar
  24. Jick H: Adverse drug effects in relation to renal function. Am J Med 62:514, 1977PubMedCrossRefGoogle Scholar
  25. Jogestrand T, Ericson F: Skeletal muscle digoxin binding in patients with renal failure. Br J Clin Pharmacol 16:109, 1983PubMedCrossRefGoogle Scholar
  26. Kaufmann B, Oloay A, Schaumann W, et al.: Pharmacokinetics of metildigoxin and digoxin in geriatric patients with normal and elevated serum creatinine levels. Clin Pharmacokinet 6:463, 1981PubMedCrossRefGoogle Scholar
  27. Keller F, Blumenthal H, Maertin R, Rietbock N: Overall pharmacokinetics during prolonged treatment of healthy volunteers with digoxin and β-methyldigoxin. Eur J Clin Pharmacol 12:387, 1977PubMedCrossRefGoogle Scholar
  28. Keller F, Molzahn M, Ingerowski R: Digoxin dosage in renal insufficiency: impracticality of basing it on the creatinine clearance, body weight and volume of distribution. Eur J Clin Pharmacol 18:433, 1980PubMedCrossRefGoogle Scholar
  29. Keller F, Schwarz A, Offermann G, Molzahn M, Distler A, Kreutz G, Weinmann J, von Leitner ER: Digitalisauslassversuch bei Hämodialysepatienten.. Dtsch Med Wochenschr 109:290, 1984PubMedCrossRefGoogle Scholar
  30. Koup JR, Jusko WJ, Elwood M, Kohli RK: Digoxin pharmacokinetics: Role of renal failure in dosage regimen design. Clin Pharmacol Ther 18:9, 1975PubMedGoogle Scholar
  31. Kramer P, Quellhorst E, Horenkamp J, Scheler F: Dialysance und prozentuale Elimination verschiedener Herzglykoside während Hämodialyse und Peritonealdialyse. Klin Wochenschr 50:609, 1972PubMedCrossRefGoogle Scholar
  32. Kramer P: Digitalis pharmacokinetics and therapy with respect to impaired renal function. Klin Wochenschr 55:1, 1977PubMedCrossRefGoogle Scholar
  33. Kramer W, Wizemann V, Thormann J, Bechtold A, Schütterle G, Lasch HG: Mechanism of altered myocardial contractility during hemodialysis: Importance of changes in the ionized calcium to plasma potassium ratio. Klin Wochenschr 63:272, 1985PubMedCrossRefGoogle Scholar
  34. Malini PL, Strocchi E, Feliciangeli G, Buscaroli A, Bonomini V, Ambrosioni E: Digitalis receptors and digoxin sensitivity in renal failure. Clin Exp Pharmacol Physiol 12:115, 1985PubMedCrossRefGoogle Scholar
  35. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:825, digoxinGoogle Scholar
  36. Ohnhaus EE, Spring P, Dettli L: Eliminationskinetik und Dosierung von Digoxin bei Patienten mit Niereninsuffizienz. Dtsch Med Wochenschr 99:1797, 1974PubMedCrossRefGoogle Scholar
  37. Ohnhaus EE, Vozeh S, Nüesch E: Absolute bioavailability of digoxin in chronic renal failure. Clin Nephrol 11:302, 1979PubMedGoogle Scholar
  38. Ohnhaus EE, Lenzinger HR, Galeazzi RL: Comparison of two different loading doses of digoxin in severe renal impairment. Eur J Clin Pharmacol 18:467, 1980PubMedCrossRefGoogle Scholar
  39. Okada R, Hager W, Graves, P, Mayersohn M, Perrier D, Marcus F: Relationship between plasma concentration and dose of digoxin in patients with and without renal failure. Circulation 58:1196, 1978PubMedCrossRefGoogle Scholar
  40. Pancarbo S, Comty C: Digoxin pharmacokinetics in continuous peritoneal dialysis. Ann Intern Med 93:639, 1980Google Scholar
  41. Peters U: Klinische und pharmakologische Grundlagen für eine kontrollierte Digitalistherapie. Z Kardiol 69:247, 1980PubMedGoogle Scholar
  42. Rambausek M, Ritz E: Digitalis in chronic renal insufficiency. Blood Purif 3:4, 1985PubMedCrossRefGoogle Scholar
  43. Smith TW, Haber E: Digitalis. N Engl J Med 289:1010, 1973PubMedCrossRefGoogle Scholar
  44. Storstein L: Studies on digitalis. V. The influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of digitoxin and digoxin. Clin Pharmacol Ther 20:6, 1976PubMedGoogle Scholar
  45. Storstein L, Janssen H: Studies on digitalis. VI. The effect of heparin on serum protein binding of digitoxin and digoxin. Clin Pharmacol Ther 20:15, 1976PubMedGoogle Scholar
  46. van der Vijgh WJF, Oe PL: Pharmacokinetic aspects of digoxin in patients with terminal renal failure. I. Off dialysis. Int. J Clin Pharmacol Biopharm 15:249, 1977PubMedGoogle Scholar
  47. van der Vijgh WJF, Oe PL: Pharmacokinetic aspects of digoxin in patients with terminal renal failure. II. On hemodialysis. Int J Clin Pharmacol Biopharm 15:255, 1977PubMedGoogle Scholar

Main references

  1. Franke G et al.: Studies on the kinetics and distribution of dihydralazine in pregnancy. Biol Res Pregnancy Perinatol 7:30, 1986PubMedGoogle Scholar
  2. lisalo E et al.: Dihydralazine therapy and acetylator phenotype. Int J Clin Pharmacol Biopharm 17:119, 1979Google Scholar
  3. Mirkin BL, Green TP, O’Dea RF: Disposition and pharmacodynamics of diuretics and antihypertensive agents in renal disease. Eur J Clin Pharmacol 18:109, 1980PubMedCrossRefGoogle Scholar
  4. Rouan MC, Campestrini J: Liquid chromatographic determination of dihydralazine and hydralazine in human plasma and its application to pharmacokinetic studies of dihydralazine. J Pharm Sci 74:1270, 1985PubMedCrossRefGoogle Scholar
  5. Schneider T et al.: Zum qualitativen Nachweis von Metaboliten des Dihydralazins beim Menschen. Pharmazie 43:33, 1988PubMedGoogle Scholar
  6. Siegmund W et al.: Quantitative Bestimmung und Kinetik von Dihydralazine bei Hypertoniepatienten. Pharmazie 40:779, 1985PubMedGoogle Scholar
  7. Siegmund W et al.: The influence of the acetylator phenotype for the clinical use of dihydralazine. Int J Clin Pharmacol Ther Toxicol 23 (Suppl 1):S74, 1985PubMedGoogle Scholar
  8. Siegmund W et al.: Preliminary conception of the metabolism of dihydralazine. Zentralbl Pharm 124:135, 1985Google Scholar
  9. Talseth T: Studies on Hydralazine. II. Elimination rate and steady-state concentration in patients with impaired renal function. Eur J Clin Pharmacol 10:311, 1976PubMedCrossRefGoogle Scholar

Main references

  1. Barnes JN, Goodwin FJ: Dihydrocodeine narcosis in renal failure. Br Med J 286:438, 1983CrossRefGoogle Scholar
  2. Barnes JN, Williams AJ, Tomson MJF, Toseland PA, Goodwin FJ: Dihydrocodeine in renal failure: Further evidence for an important role of the kidney in the handling of opioid drugs. Br Med J 290:740, 1985CrossRefGoogle Scholar
  3. Rowell FJ, Seymour RA, Rawlins MD: Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. Eur J Clin Pharmacol 25:419, 1983PubMedCrossRefGoogle Scholar
  4. Shelly MP, Park GR: Morphine toxicity with dilated pupils. Br Med J 289:1071, 1984CrossRefGoogle Scholar
  5. Vaughan DP, Beckett AH: The influence of reducing the C7–C8 double bond of codeine to give dihydrocodeine on the relative physiological availability of the drugs in man. J Pharm Pharmacol 25 (Suppi): 104P, 1973PubMedGoogle Scholar

Main references

  1. Aellig WH, Nüesch E: Comparative pharmacokinetic investigations with tritium-labelled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol 15:106, 1977Google Scholar
  2. Aellig WH: Investigation of the venoconstrictor effect of 8′-hydroxydihydroergotamine, the main metabolite of dihydro-ergotamine, in man. Eur J Clin Pharmacol 26:239, 1984PubMedCrossRefGoogle Scholar
  3. Maurer G, Frick W: Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol 26:463, 1984PubMedCrossRefGoogle Scholar

Main references

  1. David DS: Clinical studies of vitamin D analogues in renal failure. Am J Med 62:544, 1977CrossRefGoogle Scholar
  2. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 1517, chapter 65, Agents affecting calcification: calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds by RC Haynes and F Murad.Google Scholar
  3. Henning HV, Fuchs C: Renale Osteopathie. Nieren- und Hochdruckkrankh 13:235, 1984Google Scholar
  4. Kawashima H, Kurokawa K: Metabolism and sites of action of vitamin D in the kidney. Kidney Int 29:98, 1986PubMedCrossRefGoogle Scholar
  5. Suda T, Hallick RB, DeLuca HF et al.: 25-hydroxydihydrotachysterol. Synthesis and biological activity. Biochemistry 9:1651, 1970PubMedCrossRefGoogle Scholar

Main references

  1. Schaumlöffel E, Prignitz R: Isotopentechnische Untersuchungen zur Pharmakokinetik und zum Metabolismus von Dilazep am Menschen. Arzneimittelforschung (Drug Res) 22:1651, 1972Google Scholar
  2. Schaumlöffel E, Prignitz R: Über die Bioverfügbarkeit der Einzelkomponenten aus einer Kombination von Dilazep und β-Acetyl-digoxin. Arzneimittelforschung (Drug Res) 26:2208, 1976Google Scholar

Main references

  1. Bertrand ME, Dupuis BA, Lablanche JM, Tilmant PY, Thieuleux FA: Coronary hemodynamics following intravenous or intracoronary injection of diltiazem in man. J Cardiovasc Pharmacol 4:695, 1982PubMedCrossRefGoogle Scholar
  2. Bighley LD, Dimmitt DC, McGraw BF: Bioavailability of diltiazem hydrochloride formulations. Clin Res 28:587A, 1980Google Scholar
  3. Bloedow DC, Piepho RW, Nies AS, Gal J: Serum binding of diltiazem in humans. Pharmacologist 22:192, 1980Google Scholar
  4. Goebel KJ, Kölle EU: High-performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma. J Chromatogr 345:355, 1985PubMedCrossRefGoogle Scholar
  5. Kölle EU, Ochs HR, Vollmer KO: Pharmacokinetic model of diltiazem. Arzneimittelforschung (Drug Res) 33(II):972, 1983Google Scholar
  6. Kuhlmann J, Marcin S, Frank KH: Effects of nifedipine and diltiazeme on the pharmacokinetics of digoxin. Naunyn Schmiedebergs Arch Pharmacol 324 (Suppl):R81, 1983Google Scholar
  7. Mitchell LB, Jutzy KR, Lewis SJ, Schroeder JS, Mason JW: Intracardiac electrophysiologic study of intravenous diltiazem and combined diltiazem-digoxin in patients. Am Heart J 103:57, 1982PubMedCrossRefGoogle Scholar
  8. Morselli PL, et al.: Pharmacokinetics and metabolism in man (Observations on healthy volunteers and angina pectoris patients). In: Bing RJ (ed): New drug therapy with a calcium antagonist: Diltiazem Hakone Symposium ′78. Amsterdam, New York: Exerpta Medica, 1979 p 152Google Scholar
  9. Nakamura S, Suzuki T, Sugawara Y, Usuki S, Ito Y, Kume T, Yoshikawa M, Endo H, Ohashi M, Harigaya S: Metabolie fate of diltiazem. Distribution, excretion and protein binding in rat and dog. Arzneimittelforschung (Drug Res) 37(II): 1244, 1987Google Scholar
  10. Pozet N, Brazier JL, Hadj Aissa A, Khenfer D, Faucon G, Apoil E, Treager J: Pharmacokinetics of diltiazem in severe renal failure. Eur J Clin Pharmacol 24:635, 1983PubMedCrossRefGoogle Scholar
  11. Rovei V, Gomeni R, Mitchard M, Larribaud J, Blatrix C, Thebault JJ, Morselli PL: Pharmacokinetics and metabolism of diltiazem in man. Acta Cardiol (Brux) 35:35, 1980Google Scholar
  12. Shimamoto M: Surgical treatment for variant angina. Jpn J Thorac Surg 31:828, 1983Google Scholar
  13. Wagner K, Neumayer HH: Einfluß des calciumantagonisten Diltiazem auf das akute Nierenversagen nach Nierentransplantation. Ergebnisse zweier prospektiver randomisierter Studien. Med Klin 82:171, 1987Google Scholar

Main references

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:840, dimercaprolGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1426, dimethyl sulfoxideGoogle Scholar

Main references

  1. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:660, chapter 28, Prostaglandins, prostacyclin, thromboxane A2, and leukotrienes by S Moncada, RJ Flower and JR VaneGoogle Scholar
  2. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:926, chapter 39, Oxytocin, prostaglandins, ergot alkaloids, and other drugs; tocolytic agents by TW Rall and LS SchleiferGoogle Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1368, dinoprostGoogle Scholar
  4. Samuelsson B, Granström E, Green K et al.: Metabolism of prostaglandis. Ann NY Acad Sci 180:138, 1971Google Scholar

Main references

  1. Anggard E, Larsson C, Samuelsson B: The distribution of 15-hydroxy-prostaglandin dehydrogenase and prostaglandin △13-reductase in tissues of the swine. Acta Physiol Scand 81:396, 1971PubMedCrossRefGoogle Scholar
  2. Ferreira SH, Vane JR: Prostaglandins: Their disappearance from and release into the circulation. Nature 216:868, 1967PubMedCrossRefGoogle Scholar
  3. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:660, chapter 28, Prostaglandins, prostacyclin, thromboxane A2, and leukotrienes by S Moncada, RJ Flower and JR VaneGoogle Scholar
  4. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:926, chapter 39, Oxytocin, prostaglandins, ergot alkaloids, and other drugs; tocolytic agents by TW Rall and LS SchleiferGoogle Scholar
  5. Hamberg M, Samuelsson B: On the metabolism of prostaglandins E1 and E2 in man. J Biol Chem 246:6713, 1971PubMedGoogle Scholar
  6. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1370, dinoprostoneGoogle Scholar

Main references

  1. Brignoli R, Busch L, Heusser J, Keller W: New data on the experimental pharmacology and pharmacokinetic of synthetic diosmin. Minerva Med 73:186, 1982Google Scholar
  2. Oustrin J, Fauran MJ, Commanay L: A pharmacokinetic study of 3H-Diosmine. Arzneimittelforschung (Drug Res) 27(II): 1688, 1977Google Scholar

Main references

  1. Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG: Pharmacokinetics of diphenhydramide in man. J Pharmacokinet Biopharm 3:159, 1975PubMedGoogle Scholar
  2. Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI: Metabolic disposition of diphenhydramine. Clin Pharmacol Ther 16:1066, 1974PubMedGoogle Scholar

Main references

  1. Karim A, Ranney RE, Evensen KL, Clark ML: Pharmacokinetics and metabolism of diphenoxylate in man. Clin Pharmacol Ther 13:407, 1972PubMedGoogle Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1087, diphenoxylate hydrochlorideGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:454, diphenylpyraline hydrochlorideGoogle Scholar

Main references

  1. Bjornsson TD, Mahony C: Clinical pharmacokinetics of dipyridamol. Thromb Res (Suppl 4):93, 1983Google Scholar
  2. FitzGerald GA: Dipyridamole. N Engl J Med 316:1247, 1987PubMedCrossRefGoogle Scholar
  3. Harker LA, Kadatz RA: Mechanism of action of dipyridamole. Thromb Res (Suppl 4):39, 1983Google Scholar
  4. Kadatz R: Die pharmakologischen Eigenschaften der neuen corona rerweiternden Substanz 2,6-Bis(diaethanolamino)-4, 8-dipiperidino-pyrimido(5,4-d)pyridmidin. Arzneimittelforschung (Drug Res) 9:39, 1959Google Scholar
  5. Mahoney G, Wolfram KM, Cochetto D, Bjornsson TD: Dipyridamole kinetics. Clin Pharmacol Ther 31:330, 1982CrossRefGoogle Scholar
  6. Page Y, Lehot JJ, Rousselet B, Cognet JB, Buixuan B, Hoen JP, Motin J: Utilisation du dipyridamole intraveineux comme seul agent antithrombotique dans l’hemodialyse de l’insuffisance renale aigue a haut risque hemorragique. Agressologie 24:601, 1983PubMedGoogle Scholar
  7. Quellhorst E, Schuenemann B, Mietzsch G, Jacob I: Haemo- and peritoneal dialysis treatment of patients with diabetic nephropathy — a comparative study. Proc Eur Dial Transplant Assoc 15:205, 1978Google Scholar
  8. Rubin J, Adair C, Bower J: A double blind trial of dipyridamole in CAPD. Am J Kidney Dis 5:262, 1985PubMedGoogle Scholar
  9. Salter MCP, Crow MJ, Donaldson DR, Roberts TG, Rajah SM, Davison AM: Prevention of platelet deposition and thrombus formation on hemodialysis membranes: A double-blind randomized trial of aspirin and dipyridamole. Artif Organs 8:57, 1984PubMedCrossRefGoogle Scholar
  10. Schulz V, Zehle A, Kindler J, Sieberth HG: Dipyridamol-Azetyl-salizylsäure zur Prophylaxe von Shunt-Thrombosen bei chronischen Dialysepatienten. Nieren- und Hochdruckkrankh 10:49, 1981Google Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:841, disodium edetate.Google Scholar

Main references

  1. Aitio ML: Plasma concentrations and protein binding of disopyramide and mono-H-dealkyl-disopyramide during chronic oral disopyramide therapy. Br J Clin Pharmacol 11:369, 1981PubMedCrossRefGoogle Scholar
  2. Burk M, Peters U: Disopyramide kinetics in renal impairment: Determinants of interindividual variability. Clin Pharmacol Ther 34:331, 1983PubMedCrossRefGoogle Scholar
  3. Gehr TWB, Sica DA: Antiarrhythmic medications. Sem Dial 3:33, 1990CrossRefGoogle Scholar
  4. Giacomini KM, Swezey SE, Turner-Tamiyasu K, Blaschke TF: The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide. J Pharmacokinet Biopharm 10:1, 1982PubMedGoogle Scholar
  5. Henriksen H, Petersen M, Petersen F: Serum alpha-1-acid glycoprotein (orosomucoid) in uremic patients on hemodialysis. Nephron 31:24, 1982PubMedCrossRefGoogle Scholar
  6. Horn J, Hughes M: Disopyramide dialyzability. Lancet II:214, 1978Google Scholar
  7. Johnston A, Henry JA, Warrington SJ, Hamer NAJ: Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment. Br J Clin Pharmacol 10:245, 1980PubMedCrossRefGoogle Scholar
  8. Karim A: Disopyramide dialysability. Lancet II:214, 1978CrossRefGoogle Scholar
  9. Karim A, Nissen C, Azarnoff DL: Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm 10:465, 1982PubMedGoogle Scholar
  10. Koch-Weser J: Disopyramide. N Engl J Med 300:957, 1979PubMedCrossRefGoogle Scholar
  11. Morady F, Scheinman MM, Desai J: Disopyramide. Ann Intern Med 96:337, 1982PubMedGoogle Scholar
  12. Sevka MJ, Matthews SJ, Nightingale CH, Izard MW, Fieldman A, Chow MSS: Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis. Clin Pharmacol Ther 29:322, 1981PubMedCrossRefGoogle Scholar
  13. Shenn DD, Cunningham JL, Shudo I, Azarnoff DL: Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Dispos 1:133, 1980CrossRefGoogle Scholar
  14. Silberschmidt U: Disopyramidvergiftung. Schweiz Med Wochenschr 111:681, 1981PubMedGoogle Scholar
  15. Whiting B, Elliott HL: Disopyramide in renal impairment. Lancet II:1363, 1977CrossRefGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1329, distigmine bromide.Google Scholar

Main references

  1. Eldjarn L: The metabolism of tetraethyl thiuramdisulphide (Antabus, Aversan) in man, investigated by means of radioactive sulphur. Scand J Clin Lab Invest 2:202, 1950PubMedCrossRefGoogle Scholar
  2. Eneanya DI, Bianchine JR, Duran DO, Andresen BD: The actions and metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol 21:575, 1981PubMedCrossRefGoogle Scholar
  3. Fischer R, Brantner H: Über den Metabolismus des Disulfiram. Arzneimittelforschung (Drug Res) 17:1461, 1967Google Scholar
  4. Nassberger L: Hepatoxicity due to disulfiram. J Toxicol Clin Toxicol 22:403, 1984PubMedCrossRefGoogle Scholar
  5. Pedersen SB: Analysis and preliminary pharmacokinetics of disulfiram. Arch Pharm Chem Sci Ed 8:65, 1980Google Scholar

Main references

  1. Helmer J, Thirion B, Kipper R, Hottier E, Mathieu P, Giorgi C, Amrein D, Creton D, Lipp B: Interêt de la dobutamine au decours de la chirurgie cardiaque sous circulation extra-corporelle. A propos de cent observations. Ann Chir 35:533, 1981PubMedGoogle Scholar
  2. Kates RE, Leier CV: Dobutamine pharmacokinetics in severe heart failure. Clin Pharmacol Ther 24:537, 1978PubMedGoogle Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1459, dobutamine hydrochloride.Google Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1088, docusate.Google Scholar

Main references

  1. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS: Domperidone. A review of the pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24:360, 1982PubMedCrossRefGoogle Scholar
  2. Emanuel MB: The pharmacology and clinical use of domperidone. Clin Res Rev 3:15, 1983Google Scholar
  3. Heykants J, Knaeps A, Meuldermans W, Michiels M: On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats. Eur J Drug Metab Pharmacokinet 6:27, 1981PubMedCrossRefGoogle Scholar
  4. Heykants J, Hendriks R, Meuldermans W, Michiels M, Schey-grond H, Reyntjens H: On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 6:61, 1981PubMedCrossRefGoogle Scholar
  5. Lameire N, Heykants J, Scheygrond H, Reyntjens J: Plasma levels and urinary excretion of domperidone following intravenous administration to patients with severe renal insufficiency. Janssen Pharmaceutic, Clinical Research Report R 33812/50Google Scholar
  6. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, Heykants J: On the pharmacokinetics of domperidone in animals and man. III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 6:49, 1981PubMedCrossRefGoogle Scholar
  7. Michiels M, Hendriks R, Heykants J: On the pharmacokinetics of domperidone in animals and man. II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat. Eur J Drug Metab Pharmacokinet 6:37, 1981PubMedCrossRefGoogle Scholar

Main references

  1. Elias AN, Vaziri ND, Maksy M: Plasma norepinephrine, epinephrine, and dopamine levels in end-stage renal disease. Effect of hemodialysis. Arch Intern Med 145:1013, 1985PubMedCrossRefGoogle Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1460, dopamine hydrochloride.Google Scholar

Main references

  1. Baker JR, Peck CC, Raybuck BD, Owens EL, Schuster BG: Normal pharmacokinetics of doxapram in a patient with renal failure and hypothyroidism. Br J Clin Pharmacol 11:305, 1981PubMedCrossRefGoogle Scholar
  2. Baxter AD: Side effects of doxapram infusion. Eur J Intens Care Med 2:87, 1976CrossRefGoogle Scholar
  3. Bruce RB, Pitts JE, Pinchbeck F, Newman J: Excretion, distribution, and metabolism of doxapram hydrochloride. J Med Chem 8:157, 1965PubMedCrossRefGoogle Scholar
  4. Clements JA, Robson RH, Prescott LF: The disposition of intravenous doxapram in man. Eur J Clin Pharmacol 16:411, 1979PubMedCrossRefGoogle Scholar
  5. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1442, doxapram hydrochloride.Google Scholar
  6. Pitts JE, Bruce RB, Forehand JB: Identification of doxapram metabolites using high pressure ion exchange chromatography and mass spectroscopy. Xenobiotica 3:73, 1973PubMedCrossRefGoogle Scholar
  7. Robson RH, Prescott LF: A pharmacokinetic study of doxapram in patients and normal volunteers. Br J Clin Pharmacol 7:81, 1979PubMedCrossRefGoogle Scholar

Main references

  1. Bartels ACC, de Vries PMJM, Oe LP, van Bronswyk H, Donker AJM, Reveillaud RJ, Fillastre JP, Zech P: Doxazosin in the treatment of patients with mild or moderate renal insufficiency. Am Heart J 116:1772, 1988PubMedCrossRefGoogle Scholar
  2. Carlson RV, Bailey RR, Begg EJ, Cowlishaw MG, Sharman JR: Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clin Pharmacol Ther 40:561, 1986PubMedCrossRefGoogle Scholar
  3. Cubeddu LX, Fuenmayor N, Caplan N, Ferry D: Clinical pharmacology of doxazosin in patients with essential hypertension. Clin Pharmacol Ther 41:439, 1987PubMedCrossRefGoogle Scholar
  4. de Leeuw PW, Birkenhäger WH: Alpha-adrenoceptors and the kidney. J Hypertension 6 (Suppl 2):S21, 1988Google Scholar
  5. Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL: The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br J Clin Pharmacol 21 (Suppl 1):S19, 1986CrossRefGoogle Scholar
  6. Meredith PA, Elliott HL, Kelman AW, Reid JL: Doxazosin; concentration-effect relationship. Br J Clin Pharmacol 19:541 P, 1985Google Scholar
  7. Shionoiri H, Yasuda G, Yoshimura H, Umemura S, Miyajima E, Miyakawa T, Takagi N, Kaneko Y: Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 10:90, 1987PubMedCrossRefGoogle Scholar
  8. Vincent J, Elliot HL, Meredith PA, Reid JL: Doxazosin, an alpha-adrenoceptor antagonist: Pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol 15:719, 1983PubMedCrossRefGoogle Scholar
  9. Young RA, Brogden RN: Doxazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Drugs 35:525, 1988PubMedCrossRefGoogle Scholar

Main references

  1. Brown TCK, Leversha A: Comparison of the cardiovascular toxicity of three tricyclic antidepressent drugs: Imipramine, amitriptyline, and doxepin. J Toxicol Clin Toxicol 14:253, 1979CrossRefGoogle Scholar
  2. Emil K, Torosian G: Solubility and ionization characteristics of doxepin and desmethyldoxepin. J Pharm Sci 71:191, 1982CrossRefGoogle Scholar
  3. Faulkner RD, Senekjian HO, Lee CS: Hemodialysis of doxepin and desmethyldoxepin in uremic patients. Artif Organs 8:151, 1984PubMedCrossRefGoogle Scholar
  4. Seppälä T, Linnoila M, Elonen E, Mattila MJ, Mäki M: Effect of tricyclic antidepressants and alcohol on psychomotor skills related to driving. Clin Pharmacol Ther 17:515, 1975PubMedGoogle Scholar
  5. Virtanen R, Scheinin M, lisalo E: Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh) 47:371, 1980CrossRefGoogle Scholar
  6. Walter DC, Kauffman RE: Doxepin poisoning in a child. Am J Dis Child 134:202, 1980PubMedGoogle Scholar
  7. Ziegler VE, Biggs JT, Wylie LT, Rosen SH, Hawf DJ, Croyell WH: Doxepin kinetics. Clin Pharmacol Ther 23:573, 1978PubMedGoogle Scholar

Main references

  1. Bachur NR, Riggs CE, Green MR, Langone JJ, Von Vunakis H, Levine L: Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay. Clin Pharmacol Ther 21:70, 1977PubMedGoogle Scholar
  2. Benjamin RS, Riggs CE jr, Bachur NR: Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther 14:592, 1973PubMedGoogle Scholar
  3. Benjamin RS, Riggs CE, Bachur NR: Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37:416, 1977Google Scholar
  4. Burke JF, Laucius JF, Brodovsky HS, Soriano RZ: Doxorubicin hydrochloride-associated renal failure. Arch Intern Med 137:385, 1977PubMedCrossRefGoogle Scholar
  5. Chann KK, Cohen JL, Gross JF et al.: Prediction of adriamycin deposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treat Rep 62:1161, 1978Google Scholar
  6. Loveless H, Arena E, Felsted RL et al.: Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 38:593, 1978PubMedGoogle Scholar
  7. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:623, doxorubicinGoogle Scholar

Main references

  1. Böcker R, Estler CJ, Weber A: Metabolism of doxycycline. Lancet II:1155, 1982CrossRefGoogle Scholar
  2. Fabre J, Pitton JS, Virieux C, Laurencet FL, Bernhardt JP, Godel JC: Absorption, distribution et excrétion d’un nouvel antibiotique à large spectre chez l’homme. Schweiz Med Wochenschr 97:915, 1967PubMedGoogle Scholar
  3. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1219, chapter 54, Antimicrobial agents by MA Sande and GL Mandell.Google Scholar
  4. Heaney D, Eknoyan G: Minocycline and doxycycline kinetics in chronic renal failure. Clin Pharmacol Ther 24:233, 1978PubMedGoogle Scholar
  5. Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, Tillement JP: The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol 16:245, 1983PubMedCrossRefGoogle Scholar
  6. Jaffe JM, Poust RI, Feld SL, Colaizzi JL: Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans. J Pharm Sci 63:1256, 1974PubMedCrossRefGoogle Scholar
  7. Mahon WA, Wittenberg JVP, Tuffnel PG: Studies on the absorption and distribution of doxycycline in normal patients and in patients with severly impaired renal function. Can Med Assoc J 103:1031, 1970PubMedGoogle Scholar
  8. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:217, doxycyclineGoogle Scholar
  9. Neu HC: A symposium on the tetracyclines: A major appraisal. Introduction. Bull NY Acad Med 54:141, 1978Google Scholar
  10. Orr LH jr, Rudisill E jr, Brodkin R, Hamilton RW: Exacerbation of renal failure associated with doxycycline. Arch Intern Med 138:793, 1978PubMedCrossRefGoogle Scholar
  11. Spitzy KH: Fortschritte der Tetracyclinforschung. Antibiot Chemother Fortschr 10:193, 1962Google Scholar
  12. Stein W, Schoog M, Franz HE: Doxycyclin-Serumspiegel bei niereninsuffizienten Patienten. Arzneimittelforschung (Drug Res) 19:827, 1969Google Scholar

Main references

  1. Friedman H, Greenblatt DJ: The pharmacokinetics of doxylamine: Use of automated gas chromatography with nitrogen-phosphorus detection. J Clin Pharmacol 25:448, 1985PubMedGoogle Scholar
  2. Gielsdorf W, Schubert K: Zum Stoffwechsel des Doxylamin: Isolierung, Identifizierung und Synthese einiger Metabolite. J Clin Chem Clin Biochem 19:485, 1981PubMedGoogle Scholar
  3. Kohlhof KJ, Stump D, Zizzamia JA: Analysis of doxylamine in plasma by high-performance liquid chromatography. J Pharm Sci 72:961, 1983PubMedCrossRefGoogle Scholar
  4. Sheldon JM, Weller KE, Haley RR, Fulton JK: Clinical observations with decapryn; new antihistaminic compound. Univ Hosp Bull Ann Arbor 14:13, 1948PubMedGoogle Scholar
  5. Snyder FH, Klahm GR, Werner HW: Studies on the metabolism of 2-[α-(2-dimethylaminoethoxy)-α-methylbenzyl]-pyridine succinate (Decapryn succinate). J Am Pharm Assoc 37:420, 1948Google Scholar

Main references

  1. Cressman WA, Plostnieks J, Johnson PC: Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration. Anesthesiology 38:363, 1973PubMedCrossRefGoogle Scholar
  2. Ghoneim MM, Korttila K: Pharmacokinetics of intravenous anaesthetics: Implications for clinical use. Clin Pharmacokinet 2:344, 1977PubMedCrossRefGoogle Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:735, droperidolGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1397, dydrogesteroneGoogle Scholar

Main references

  1. Lee CSC, Wang LH, Majeske BL, Marbury TC: Pharmacokinetics of dyphylline elimination by uremic patients. J Pharmacol Exp Ther 217:340, 1981PubMedGoogle Scholar
  2. Simons FER, Simons KJ, Bierman CW: The pharmacokinetics of dihydroxypropyltheophylline: A basis for rational therapy. J Allergy Clin Immunol 56:347, 1975PubMedCrossRefGoogle Scholar
  3. Simons KJ, Simons FER: Urinary excretion of dyphylline in humans. J Pharm Sci 68:1327, 1979PubMedCrossRefGoogle Scholar
  4. Stablein JJ, Samaan SS, Bukantz SC, Lockey RF: Pharmacokinetics and bioavailability of three dyphylline preparations. Eur J Clin Pharmacol 25:281, 1983PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1991

Authors and Affiliations

  • Günter Seyffart
    • 1
  1. 1.Dialysis CenterBad HomburgGermany

Personalised recommendations